Yu Ren Selected Research

Catenins

1/2022	PROX1 promotes breast cancer invasion and metastasis through WNT/β-catenin pathway via interacting with hnRNPK.
1/2019	A Compound AC1Q3QWB Selectively Disrupts HOTAIR-Mediated Recruitment of PRC2 and Enhances Cancer Therapy of DZNep.
1/2019	Targeted design and identification of AC1NOD4Q to block activity of HOTAIR by abrogating the scaffold interaction with EZH2.
1/2019	Radiation-induced glucocorticoid receptor promotes CD44+ prostate cancer stem cell growth through activation of SGK1-Wnt/β-catenin signaling.
1/2017	Tumor Necrosis Factor (TNF)-α-Induced Protein 8-like-2 (TIPE2) Inhibits Proliferation and Tumorigenesis in Breast Cancer Cells.
1/2017	Suppression of the Growth and Invasion of Human Head and Neck Squamous Cell Carcinomas via Regulating STAT3 Signaling and the miR-21/β-catenin Axis with HJC0152.
4/2015	HOTAIR is a therapeutic target in glioblastoma.
3/2014	MicroRNA-566 activates EGFR signaling and its inhibition sensitizes glioblastoma cells to nimotuzumab.
9/2012	PTEN activation sensitizes breast cancer to PI3-kinase inhibitor through the β-catenin signaling pathway.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Yu Ren Research Topics

Disease

78	Neoplasms (Cancer) 08/2022 - 11/2005
36	Breast Neoplasms (Breast Cancer) 04/2022 - 01/2007
20	Neoplasm Metastasis (Metastasis) 08/2022 - 11/2011
18	Renal Cell Carcinoma (Grawitz Tumor) 07/2022 - 11/2014
11	Squamous Cell Carcinoma of Head and Neck 10/2021 - 05/2014
11	Carcinogenesis 01/2021 - 01/2007
11	Glioblastoma (Glioblastoma Multiforme) 01/2019 - 01/2010
10	Glioma (Gliomas) 01/2019 - 01/2010
7	Prostatic Neoplasms (Prostate Cancer) 08/2022 - 03/2018
7	Carcinoma (Carcinomatosis) 12/2021 - 11/2014
5	Inflammation (Inflammations) 01/2021 - 04/2016
4	Wounds and Injuries (Trauma) 07/2022 - 01/2020
4	Triple Negative Breast Neoplasms 01/2022 - 11/2011
3	Hypoxia (Hypoxemia) 01/2022 - 03/2014
3	Fibrosis (Cirrhosis) 11/2021 - 01/2016
3	Heart Failure 07/2021 - 01/2019
3	Melanoma (Melanoma, Malignant) 01/2021 - 01/2020
3	Kidney Neoplasms (Kidney Cancer) 12/2018 - 12/2016
2	Pancreatic Neoplasms (Pancreatic Cancer) 11/2022 - 01/2015
2	Ischemic Stroke 02/2022 - 01/2021
2	Dementia (Dementias) 01/2022 - 01/2022
2	Body Weight (Weight, Body) 01/2022 - 08/2015
2	Obesity 01/2022 - 01/2021
2	Heart Arrest (Cardiac Arrest) 01/2022 - 08/2020
2	Cognitive Dysfunction 01/2022 - 01/2022
2	Allergic Rhinitis 01/2021 - 12/2020
2	Hemorrhage 01/2021 - 06/2015
2	Colonic Neoplasms (Colon Cancer) 01/2021 - 12/2020
2	Ductal Carcinoma 11/2020 - 06/2019
2	Lymphatic Metastasis 08/2020 - 07/2015
2	Mastitis 04/2020 - 01/2015
2	Adenocarcinoma of Lung 11/2018 - 11/2015

Drug/Important Bio-Agent (IBA)

22	Proteins (Proteins, Gene)FDA Link 04/2022 - 01/2007
16	MicroRNAs (MicroRNA)IBA 01/2020 - 01/2010
14	Long Noncoding RNAIBA 08/2022 - 01/2015
11	Biomarkers (Surrogate Marker)IBA 01/2022 - 08/2016
9	CateninsIBA 01/2022 - 09/2012
8	Pharmaceutical PreparationsIBA 12/2020 - 01/2007
7	RNA (Ribonucleic Acid)IBA 10/2021 - 01/2015
6	Biological ProductsIBA 11/2021 - 11/2015
6	Estrogen ReceptorsIBA 08/2020 - 01/2011
5	Transcription Factors (Transcription Factor)IBA 04/2022 - 03/2010
5	Interleukin-6 (Interleukin 6)IBA 01/2021 - 10/2014
5	Messenger RNA (mRNA)IBA 08/2020 - 11/2008
4	Therapeutic UsesIBA 11/2021 - 03/2014
4	Hormones (Hormone)IBA 04/2021 - 01/2011
4	LuciferasesIBA 01/2021 - 11/2011
4	LipidsIBA 01/2021 - 01/2017
4	STAT3 Transcription Factor (Signal Transducer and Activator of Transcription 3)IBA 01/2019 - 05/2014
4	Paclitaxel (Taxol)FDA LinkGeneric 04/2016 - 01/2010
3	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 11/2022 - 01/2017
3	Progesterone Receptors (Progesterone Receptor)IBA 08/2020 - 01/2013
3	sinomenineIBA 04/2020 - 03/2015
3	Protein Serine-Threonine Kinases (Protein-Serine-Threonine Kinase)IBA 01/2020 - 03/2010
3	AndrogensIBA 01/2020 - 02/2010
3	Glucocorticoid Receptors (Glucocorticoid Receptor)IBA 01/2020 - 01/2019
3	Small Interfering RNA (siRNA)IBA 01/2019 - 11/2014
3	WP1066IBA 01/2018 - 05/2014
3	Cyclic AMP (AMP, Cyclic)IBA 06/2017 - 01/2013
3	Antineoplastic Agents (Antineoplastics)IBA 01/2017 - 11/2011
3	Antisense OligonucleotidesIBA 12/2015 - 02/2010
3	Poly(amidoamine)IBA 02/2010 - 01/2010
2	HydrogelsIBA 07/2022 - 11/2021
2	SynucleinsIBA 01/2022 - 01/2022
2	Anti-Bacterial Agents (Antibiotics)IBA 01/2022 - 10/2007
2	Hyaluronic Acid (Hyaluronan)IBA 11/2021 - 01/2020
2	ErbB Receptors (EGF Receptor)IBA 10/2021 - 03/2014
2	Cetuximab (Erbitux)FDA Link 10/2021 - 01/2018
2	Indicators and Reagents (Reagents)IBA 01/2021 - 11/2008
2	CaspasesIBA 01/2021 - 01/2019
2	LigandsIBA 01/2021 - 01/2020
2	Angiogenesis Inducing Agents (Angiogenesis Factor)IBA 01/2021 - 03/2015
2	AntigensIBA 01/2020 - 01/2014
2	human ERBB2 proteinIBA 06/2019 - 01/2013
2	Phenobarbital (Luminal)FDA Link 06/2019 - 05/2014
2	ChromatinIBA 01/2019 - 11/2018
2	Polycomb Repressive Complex 2IBA 01/2019 - 01/2015
2	Adenosine Triphosphate (ATP)IBA 01/2019 - 11/2015
2	Mifepristone (RU 486)FDA Link 01/2019 - 01/2019
2	Cisplatin (Platino)FDA LinkGeneric 01/2018 - 12/2014
2	Carrier Proteins (Binding Protein)IBA 06/2017 - 03/2016
2	ElementsIBA 06/2017 - 03/2016
2	Metalloproteases (Metalloproteinases)IBA 06/2017 - 02/2011
2	Tamoxifen FDA LinkGeneric 01/2017 - 11/2015
2	Minichromosome Maintenance Complex Component 7IBA 01/2017 - 01/2017
2	Simvastatin (Zocor)FDA LinkGeneric 01/2017 - 01/2017
2	Oncogene Proteins (Oncogene Protein)IBA 11/2016 - 01/2007
2	CytokinesIBA 10/2016 - 10/2014
2	Doxorubicin (Adriamycin)FDA LinkGeneric 04/2016 - 02/2014
2	NF-kappa B (NF-kB)IBA 10/2014 - 03/2010
2	Epidermal Growth Factor (EGF)IBA 05/2014 - 01/2014
2	nimotuzumabIBA 03/2014 - 01/2014

Therapy/Procedure

34	Therapeutics 01/2022 - 01/2010
10	Drug Therapy (Chemotherapy) 06/2021 - 02/2010
6	Radiotherapy 12/2021 - 01/2013
2	Induced Hypothermia 01/2022 - 08/2020
2	Segmental Mastectomy (Lumpectomy) 12/2021 - 01/2017
2	Immunotherapy 01/2021 - 01/2020
2	Nephrectomy 01/2020 - 01/2014
2	Intravenous Administration 04/2016 - 03/2014